日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机 II 期试验,比较乐伐替尼联合依维莫司与卡博替尼治疗 PD-1 免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者的疗效(LenCabo)

Hahn, A W; Chahoud, J; Skelton, W P; Yuan, Y; Zurita-Saavedra, A J; Kovitz, C; Alhalabi, O; Campbell, M T; Jonasch, E; Lin, J K; Desai, M; Santos, M J M N; Hwang, H; Corn, P G; Msaouel, P; Tannir, N M

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

通过 FoundationOne CDx 检测鉴定的 TMB-H 肿瘤中,验证免疫检查点阻断疗法对癌症类型依赖性获益的有效性

McGrail, D J; Pilié, P G; Rashid, N U; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, A B; Ueno, N T; Ferrarotto, R; Chang, J T; Lin, S-Y

VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions

VHL-P138R 和 VHL-L163R 新变体:涉及 HIF 依赖性和 HIF 非依赖性作用的 VHL 致病机制

Cecilia Mathó, María Celia Fernández, Jenner Bonanata, Xian-De Liu, Ayelen Martin, Ana Vieites, Gabriela Sansó, Marta Barontini, Eric Jonasch, E Laura Coitiño, Patricia Alejandra Pennisi

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

高肿瘤突变负荷无法预测所有癌症类型的免疫检查点阻断反应

McGrail, D J; Pilié, P G; Rashid, N U; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, A B; Lim, B; Ueno, N T; Litton, J K; Ferrarotto, R; Chang, J T; Moulder, S L; Lin, S-Y

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

一线免疫检查点抑制剂治疗后接受二线VEGFR-TKI治疗的转移性透明细胞肾细胞癌患者的预后

Shah, A Y; Kotecha, R R; Lemke, E A; Chandramohan, A; Chaim, J L; Msaouel, P; Xiao, L; Gao, J; Campbell, M T; Zurita, A J; Wang, J; Corn, P G; Jonasch, E; Motzer, R J; Sharma, P; Voss, M H; Tannir, N M

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

一项MK-2206与依维莫司治疗难治性肾细胞癌的随机II期研究

Jonasch, E; Hasanov, E; Corn, P G; Moss, T; Shaw, K R; Stovall, S; Marcott, V; Gan, B; Bird, S; Wang, X; Do, K A; Altamirano, P F; Zurita, A J; Doyle, L A; Lara, P N Jr; Tannir, N M

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

转移性肾细胞癌患者的舒尼替尼替代给药方案

Kalra, S; Rini, B I; Jonasch, E

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

接受其他靶向治疗后疾病进展的转移性透明细胞肾细胞癌患者,接受帕唑帕尼治疗后的预后

Matrana, M R; Duran, C; Shetty, A; Xiao, L; Atkinson, B J; Corn, P; Pagliaro, L C; Millikan, R E; Charnsangave, C; Jonasch, E; Tannir, N M

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

对转移性肾细胞癌患者血浆中的细胞因子和血管生成因子 (CAF) 进行分析,以选择索拉非尼治疗

Zurita A J, Jonasch E, Wang X, Khajavi M, Yan S, Du D Z, Xu L, Herynk M H, McKee K S, Tran H T, Logothetis C J, Tannir N M, Heymach J V

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

接受靶向治疗而不行细胞减灭性肾切除术的转移性肾细胞癌患者的预后

Richey, S L; Culp, S H; Jonasch, E; Corn, P G; Pagliaro, L C; Tamboli, P; Patel, K K; Matin, S F; Wood, C G; Tannir, N M